The Global COVID-19 Rapid Antigen Test Kits Market Size, Share, Trends, Analysis By

  • Prescription: Professional and At-Home/OTC
  • End-User: Hospitals & Clinics, Laboratories, Individuals/Homecare, and Others
  • Geography: Europe, North America, APAC, Middle East & Africa, and Latin America

Industry Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share, & Forecast, 2022-2027

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Enquire Now Download Free Sample

Most Exhaustive Report


292 Pages


127 Tables


114 Charts


5 Regions


27 Countries


50 Companies


3 Market Segment


Report Attribute Details
CAGR (26.33%)
MARKET SEGMENTS Prescription, End-User, and Geography
GEOGRAPHIC ANALYSIS Europe, North America, APAC, Middle East & Africa, and Latin America
COUNTRIES COVERED UK, France, Russia, Italy, Spain, Germany, Netherland, Poland, US, Canada, India, Australia, South Korea, Malaysia, China, Philippines, Japan, Turkey, Saudi Arabia, South Africa, Iran, Brazil, Mexico, Argentina, Peru, Columbia, and Chile


The COVID-19 rapid antigen tests market is expected to reach $743.07 million by 2027. Antigen tests are commonly used in the diagnosis of pathogens, including influenza viruses and respiratory syncytial viruses. These tests are immunoassays that detect specific viral antigen and confirms the presence or absence of viral infection. Rapid antigen tests are currently authorized to be performed on nasal or nasopharyngeal swab specimens placed directly into the immunoassay’s extraction buffer or reagent. The currently available rapid antigen tests include point-of-care (POC) and laboratory-based tests, as well as self-tests performed at home, and they are commercially available to people of any age. A rapid antigen test is one of the widely used diagnostic tests to diagnose COVID-19 presence in an individual with or without symptoms. It offers a faster result and is relatively less expensive than PCR (polymerase chain reaction) or antibody tests. 

The global COVID-19 rapid antigen tests market is a new demanding market. The market is growing at a rapid pace due to the COVID-19 pandemic and will become a normal market like other infectious diseases.

The testing plays a significant role in containing and mitigating the pandemic by identifying the infected individual and stopping further person-to-person transmission. Rapid antigen testing is one of the primarily performed COVID-19 tests globally. This diagnosis determines the portion of virus protein and can give results within 15 minutes. Initially, the PCR was considered the gold standard for COVID-19 diagnosisHowever, over time, usage of rapid diagnostics kits has increased, and also, the vendors have introduced highly sensitive COVID-19 rapid tests kits.

Benefits of COVID-19 Rapid Antigen Testing

One of the significant advantages of people preferring rapid antigen testing devices is its quick results and more economic ability than other testing devices in the market. The demand for rapid COVID-19 antigen test kits is growing due to their low cost and easy use. The government in many countries is widely making the test kits available at a discounted price, which is one of the major factors boosting the adoption rate of home test kits.

Raise in Infection Spread

Multiple variants of the COVID-19 virus were identified across the globe. Governments started providing authorization for the emergency use of numerous test kits to increase access to COVID-19 tests. Countries such as the US and the UK started providing free home test kits, which has led to the high adoption of home test kits as these devices can be used without professional guidance.

Technological Advancements in COVID-19 Rapid Testing

Vendors designed various new rapid testing kits such as cups and cards and smart test kits, which were more sensitive and provided better results, almost equal to gold-standard PCR testing. There were painless rapid testing kits that used saliva samples. Test kits providing results in a shorter time were also introduced in the market. These advancements drive the usage of rapid testing over other COVID-19 testing kits. For instance, CoviFind COVID-19 Rapid Antigen Self-Test, a non-prescription product manufactured by Meril Diagnostics, an India-based, global medical company, has approval from ICMR for regular use in India self-test and is easily accessible.

Large academic institutes, and companies distributed home test kits at no cost to their stakeholders. This was a precautionary measure and peace of mind for the students and workers, helping people decide on the pandemic. Several steps are taken by the government, corporate companies, and academic institutes to increase the usage of COVID-19 rapid testing kits.


COVID-19 Rapid Antigen Testing Market

COVID-19 Rapid Test Market

Download a Free Sample!

Mass Testing Strategy Among Countries & Robust Fundings for COVID-19 Testing

Robust testing strategies are seen as a significant aspect of preparedness and response to the COVID-19 pandemic, early detection of infection rates, and transmission, among others. Many countries started conducting COVID-19 mass testing strategies to reduce the spread of infections. People traveling from other countries were tested in airports, and migrating within-country required covid-19 certificates. Many were also tested on the spot using rapid test kits to reduce the spread of infections. Many NGOs, large regulatory bodies, and companies started manufacturing the COVID-19 test kits to tap the opportunity in the market. The increased investments made the companies increase their production volume. This, in turn, vastly increased the opportunities for COVID-19 rapid testing in the market.

One of the major limitations of rapid testing is the increased number of false-positive and negative results. There were cases with false-negative and false-positive reports in a set of COVID-19 test kits. People with COVID-19 symptoms were tested negative and tested positive when checked with alternative COVID-19 testing. These instances reduced the usage of COVID-19 rapid test kits in a few countries. Some countries like China still consider using RT-PCR tests for screening people.

Developed countries like the US, Germany, the UK, France, Italy, Canada, and Spain are conducting many COVID-19 rapid tests through OTC/Home tests and healthcare settings. People in developed countries purchase home testing kits and preserve them for future use. This is not the case in developing countries. Only symptomatic people prefer buying the kits to get tested. This trend differentiates the consumption pattern among the nations. A country like Canada has ordered more rapid test kits than its population count, whereas India has not.


Europe dominated the COVID-19 rapid testing market by geography segment. However, APAC is expected to grow at a faster rate. Due to the increased adoption of rapid testing and quicker approval of COVID-19 rapid home test kits in Europe, the COVID-19 rapid antigen test kits market in Europe will remain dominant. North America was the second-largest market with faster product approvals, launches, and better distribution of home test kits. The United States launched new initiatives like testing with treatments, which means the treatment is provided as soon as the person is tested positive. These kinds of initiatives will primarily drive the usage of rapid test kits in the US. Hospitals & Clinics were the most significant users in the COVID-19 antigen test market. Mainly professional rapid testing was used in the hospitals & clinics segments. Individual segments had faster Covid-19 antigen test kits market growth rates. The demand for home test kits is increasing, and many companies are investing in manufacturing large volumes as there is a surge for home test kits in the market.

Professional test kits are in demand compared to other OTC/ Home test kits. After the complete vaccination process, the number of people suffering from COVID-19 infections will decrease. It will be like other viral infectious diseases. This will limit the people to get tested in healthcare settings like hospitals & clinics, compared to OTC/home conditions. This will significantly impact the OTC/home test kits, and they might become obsolete over time. Technological advancements like increased sensitivity and faster results are driving the usage of professional test kits in the industry. Since multiple strains of COVID-19 are encountered in the industry, impacting a large population, OTC/ Home test kits are expected to continue until many cases are reported.

Frequently Asked Questions

What was the size of the COVID-19 rapid antigen test kits market in 2021?

The global Covid-19 rapid antigen tests market was valued at USD 4.6 billion in 2021.

Who are the key players in the COVID-19 rapid antigen test kits market?

Key players include Abbott, BD, F.Hoffmann-La Roche, Thermo Fisher Scientific, and Bio-Rad Laboratories.

What are the growth opportunities in the Rapid Covid-19 antigen test kits market?

Technological advancements in covid-19 rapid test kits and increasing mass testing for covid-19 are creating huge growth opportunities for the vendors in the rapid Covid-19 antigen test kits market.

What are the strategies adopted by the players in the COVID-19 rapid antigen test kits market?

Key players are engaging in strategic acquisitions as part of their inorganic growth strategy to improve sales and profit margins. Strategic M&As continue to be an important competitive strategy for key players to expand product offerings, access new technology, and increase rapid Covid-19 antigen test kits market share.

What are the growth enablers in the COVID-19 rapid antigen test kits market?

Robust funding and investments to scale up covid-19 rapid antigen tests and increasing donations of covid-19 rapid antigen test kits are some of the growth enablers in the market.

Download Free Sample


The report considers the present scenario of the COVID-19 rapid antigen test kits market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.

Base Year: 2021

Forecast Year: 2022-2027

Key Vendors

  • Abott
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • BD
  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories

Other Prominent Vendors

  • AccuBioTech
    • Business Overview
    • Product Offerings
  • AIVD Biotech
  • ANP Technologies
  • Angstrom Biotech
  • ARISTA Biotech
  • Assure Tech (Hangzhou)
  • Biolidics
  • BioMaxima SA
  • Biopanda Reagents
  • Biosynex
  • BIOHIT Healthcare
  • BioSpeedia
  • BioMedomics
  • BioTeke
  • BTNX
  • CTK Biotech
  • Celltrion
  • Chembio Diagnostics
  • Ellume
  • Empowered Diagnostics
  • Getein Biotech
  • GenBody
  • Hangzhou Alltest Biotech
  • Hangzhou Clongene Biotech
  • Healgen Scientific
  • Wondfo
  • KH Medical
  • Lepu Medical Technology
  • LumiraDx
  • Mylab Discovery Solutions
  • Meril Life Sciences
  • Medicofarma
  • nal von minden
  • OraSure Technologies
  • PerkinElmer
  • Quidel
  • Siemens Healthineers
  • SD Biosensor
  • Tianjin Era Biology Technology
  • Xiamen Boson Biotech
  • Zhejiang Orient Gene Biotech

Market Segmentation by Prescription

  • Professional
  • At-Home/OTC

Market Segmentation by End-User

  • Hospitals & Clinics
  • Laboratories
  • Individuals/Homecare
  • Others

Market Segmentation by Geography

  • Europe
    • UK
    • France
    • Russia
    • Italy
    • Spain
    • Germany
    • Netherland
    • Poland
  • North America
    • US
    • Canada
  • APAC
    • India
    • Australia
    • South Korea
    • Malaysia
    • China
    • Philippines
    • Japan
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • Iran
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Peru
    • Columbia
    • Chile

For more details, please reach us at

For more details, please reach us at

Select a license type that suits your business needs

single-user Single User Licence
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Our Clients Speak


"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date